--- title: "Omeros (OMER) Turns Profitable As Fair Value Questions Come Into View" type: "News" locale: "en" url: "https://longbridge.com/en/news/296706352.md" description: "Omeros (OMER) reported a shift to net income in Q2 and H1 2026, driving significant stock momentum with 96.83% one-month returns. Despite this surge, the stock trades at a steep discount to analyst targets, suggesting it is undervalued based on fair value estimates of $33. This valuation relies on expected revenue scaling, margin improvements, and cash inflows from a Novo Nordisk transaction. However, risks include potential regulatory setbacks for YARTEMLEA in Europe or delays in funding." datetime: "2026-08-23T15:38:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296706352.md) - [en](https://longbridge.com/en/news/296706352.md) - [zh-HK](https://longbridge.com/zh-HK/news/296706352.md) generator: "portal-rs" --- # Omeros (OMER) Turns Profitable As Fair Value Questions Come Into View Omeros (OMER) is in focus after reporting a shift to net income in its second quarter and first half of 2026, replacing prior year losses and prompting fresh attention on the stock. See our latest analysis for Omeros. That shift to profit has coincided with sharp share price momentum for Omeros, with a 96.83% 1 month share price return and a 68.15% 3 month share price return. This has contributed to a very large 1 year total shareholder return. If strong recent gains in Omeros have you reviewing the broader biotech and healthcare opportunity, you might also want to look at AI driven healthcare stocks using this discovery screener: 40 healthcare AI stocks After a move like this, Omeros now trades at a steep 71% discount to the average analyst target of $33. Is the market applying sensible caution, or has the recent profit swing shifted the valuation case too far behind events? ## Most Popular Narrative: 41.6% Undervalued Based on the most followed narrative, Omeros screens as materially undervalued, with a fair value of $33 against the latest close at $19.27. That gap rests on a set of ambitious pipeline and regulatory expectations. > *The expected closing of the Novo Nordisk transaction, with US$240 million upfront and up to US$2.1 billion in total potential consideration plus royalties, would remove near term debt obligations and extend the cash runway. This could ease funding risk and support future revenue and earnings growth from the remaining pipeline.* *Read the complete narrative.* Want to see what sits underneath that fair value call? The narrative leans on aggressive revenue scaling, shifting margins and a rich future earnings multiple. The mix may surprise you. **Result: Fair Value of $33 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the Omeros story could change quickly if YARTEMLEA faces regulatory setbacks in Europe or if expected Novo Nordisk cash inflows are delayed. Find out about the key risks to this Omeros narrative. ## Next Steps Given the mix of optimism and concern around Omeros, it makes sense to move quickly and review the underlying data yourself. To weigh those trade offs in more detail and shape your own view, start with the 4 key rewards and 4 important warning signs. ## Looking for more investment ideas beyond Omeros? If Omeros has sharpened your interest, do not stop here. Broadening your watchlist now could help you spot opportunities before they become crowded. - Target reliable income by reviewing companies we group as potential income pillars through the 12 dividend fortresses. - Hunt for quality at a discount by checking companies that screen well on valuation through the 48 high quality undervalued stocks. - Prioritise resilience by focusing on companies that combine robust finances with measured risk in the 75 resilient stocks with low risk scores. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [OMER.US](https://longbridge.com/en/quote/OMER.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md) - [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md) ## Related News & Research - [Insider Shake-Up at Omeros as Key Director Sells Off a Chunk of Shares](https://longbridge.com/en/news/296662749.md) - [Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/295993093.md) - [Omeros (OMER), Why Is Its Latest Update Drawing Attention?](https://longbridge.com/en/news/295990263.md) - [Omeros director Joseph L. Schocken files initial beneficial ownership statement](https://longbridge.com/en/news/296288452.md) - [Omeros director Thomas J. Cable disposes of 15,000 common shares for $276,772.50](https://longbridge.com/en/news/296655425.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**